Emphysema Clinical Trial
Official title:
Effects of Exercise Training on Systemic Inflammation an Muscle Repair According to the Chronic Obstructive Pulmonary Disease Phenotype
AIM: To identify those mechanisms involved in the systemic and muscular response to exercise
treatment, in two different Obstructive Chronic Pulmonary Disease (COPD) phenotypes
(emphysema and non-emphysema). The investigators will evaluate the effect of exercise
training, on exercise outcomes, peripheral muscle strength measures, dyspnea and quality of
life indices, and markers of systemic inflammation and muscle repair.
SUBJECTS: The investigators will study 30 COPD patients in GOLD II-IV stages, with
symptomatic disease. Patients will be differentiated into 2 different phenotypes:
predominant-emphysema and non-predominant emphysema (15 subjects for each group), according
to high resolution computed tomography (HRCT) scanning images, and after the specific
analysis with the MeVisPulmo software. After patients are typified, they will be included in
the 12- wk training programme. MEASURES(pre&post-training):Basic blood analysis, EKG,
spirometry, blood gases, pletysmography, gas diffusion, maximal inspiratory and expiratory
pressure (MIP,MEP), bioimpedanciometry, 1RM test and isometric strength determination, 6-min
walking test (6MWT), maximal and submaximal cycle-ergometry, and dyspnea using the Mahler's
Basal and Transitional Dyspnoea Indexes (BDI/TDI) and quality of life (Chronic Respiratory
Disease Questionnaire [(CRDQ]) evaluation. Besides, the investigators will measure blood PCR
and cytokines levels (IL6, IL8, IL10, IL12, TNF-α, IGF-1, and MIC-A & MIC-B). Muscle
biopsies will be made (quadriceps) for detection of TNF-α, TNFR-I, TNFR-II, IGF-1Ea and MGF,
IGF-1R, genes bound to biogenesis, markers of cell lesion-stress and myosin heavy chains
(MyHC) type I and II, N-CAM/CD56 and Met & Desmin
Status | Recruiting |
Enrollment | 30 |
Est. completion date | December 2012 |
Est. primary completion date | December 2012 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 45 Years to 85 Years |
Eligibility |
Inclusion Criteria: - COPD patients diagnosed according to criteria established by the ATS (American Thoracic Society) and the SEPAR (Spanish Society of Pneumology and Thoracic Surgery) obstruction presenting moderate to severe airway obstruction (FEV1 <60%) and a clinical impact of their disease. Patients should be stable and appropriate therapy, and must not have suffered exacerbations of the disease over a period of three months before the study, and without treatment with oral corticosteroids for at least the same period. Exclusion Criteria: - Other cardio-respiratory diseases, cardiovascular, neuromuscular or metabolic might interfere with the results. - Systemic diseases, alcohol intake (> 80 g / day) or treatment with drugs with potential effect on muscle structure - Inability or disagree to participate in an exercise program. |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Universitario Virgen del Rocío | Sevilla |
Lead Sponsor | Collaborator |
---|---|
Hospitales Universitarios Virgen del Rocío | Fondo de Investigacion Sanitaria |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from baseline in TNF-alpha and its receptors, muscle isoforms of IGF-1 and its receptor in samples of quadriceps muscle satellite cells at 3 moths. | Compare these values according to the phenotype of the patient (airway-predominant vs. emphysema-predominant) and assess the effect of the training program, according to the phenotype, the regenerative potential and muscle remodeling. | Baseline and end of follow-up period of 3 moths | No |
Secondary | Pax7, M-cadherin and Myo-D and its receptor in samples (molecules and repair-myogenesis) of quadriceps muscle satellite cells. | Compare these values according to the phenotype of the patient (airway-predominant vs. emphysema-predominant) and assess the effect of the training program, according to the phenotype, the regenerative potential and muscle remodeling. | Baseline and end of follow-up period of 3 moths | No |
Secondary | MIC-A and MIC-B soluble in serum. | Compare these values according to the phenotype of the patient (airway-predominant vs. emphysema-predominant) and assess the effect of the training program, according to the phenotype. Determine whether the presence of these substances impact in terms of exercise capacity, nutritional status and muscle function. | Baseline and end of follow-up period of 3 moths. | No |
Secondary | CRP, IL6, IL8, IL10, IL12, TNF alpha, IGF-1 (systemic inflammatory profile) in serum. | Compare these values according to the phenotype of the patient (airway-predominant vs. emphysema-predominant) and assess the effect of the training program, according to the phenotype. Determine whether the presence of these substances impact in terms of exercise capacity, nutritional status and muscle function. | Baseline and end of follow-up period of 3 moths. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05825261 -
Exploring Novel Biomarkers for Emphysema Detection
|
||
Completed |
NCT02914340 -
REACH SVS Control Patient Cross-Over Study
|
N/A | |
Completed |
NCT02999685 -
Home-based Health Management of Chronic Obstructive Lung Disease (COPD) Patients
|
N/A | |
Completed |
NCT02232841 -
Electrical Impedance Imaging of Patients on Mechanical Ventilation
|
N/A | |
Completed |
NCT02238327 -
Longitudinal Evaluation of HIV-associated Lung Disease Phenotypes
|
||
Withdrawn |
NCT01908933 -
Study of the AeriSeal System Treatment in Patients With Advanced Non-Upper Lobe Predominant Heterogeneous Emphysema
|
Phase 3 | |
Completed |
NCT01615484 -
Ex-vivo Perfusion and Ventilation of Lungs Recovered From Non-Heart-Beating Donors to Assess Transplant Suitability
|
N/A | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01710449 -
Evaluation of Regional Ventilation Using 19F MRI of Inert Perfluorinated Gases Mixed With Oxygen
|
Phase 1 | |
Completed |
NCT00475007 -
Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema
|
N/A | |
Suspended |
NCT00523094 -
Vibration Response Imaging (VRI) in Patients That Are Candidates for Undergoing Pulmonary Operation Procedure
|
N/A | |
Recruiting |
NCT00129350 -
Assessment of Heart and Heart-Lung Transplant Patient Outcomes Following Pulmonary Rehabilitation
|
Phase 1 | |
Completed |
NCT01953523 -
Safety and Clinical Outcomes Study: SVF Deployment for Orthopedic, Neurologic, Urologic, and Cardio-pulmonary Conditions
|
N/A | |
Completed |
NCT00000621 -
Feasibility of Retinoic Acid Treatment in Emphysema (FORTE)
|
Phase 2 | |
Completed |
NCT00005292 -
Alpha1-antitrypsin Deficiency Registry
|
N/A | |
Recruiting |
NCT04537182 -
Surgical Compared to Bronchoscopic Lung Volume Reduction in Patients With Severe Emphysema
|
N/A | |
Active, not recruiting |
NCT02713347 -
Advancing Symptom Alleviation With Palliative Treatment
|
N/A | |
Recruiting |
NCT04302272 -
STRIVE Post-Market Registry Study
|
||
Completed |
NCT04435327 -
Lung Damage Caused by SARS-CoV-2 Pneumonia (COVID-19)
|
||
Completed |
NCT03636347 -
A 12-week Study Treating Participants Who Have alpha1-antitrypsin-related COPD With Alvelestat (MPH966) or Placebo.
|
Phase 2 |